ImmunoGen, Inc. Announces Webcast of its Presentation at the BIO Investor Forum 2005.CAMBRIDGE, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the BIO Investor Forum 2005 will be webcast live. The presentation is scheduled to begin at 2:20 pm PT (5:20 pm ET) on Wednesday, October 19, 2005, and will be given at the Palace Hotel in San Francisco, California “San Francisco” redirects here. For other uses, see San Francisco (disambiguation). The City and County of San Francisco (EN IPA: [sænfrənˈsɪskoʊ] . The presentation will provide an update on ImmunoGen. The webcast can be accessed through the "Investor Relations Investor relations The process by which the corporation communicates with its investors. " section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the presentation will be available at the same location until October 26, 2005. About ImmunoGen, Inc. ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug prodrug /pro·drug/ (-drug) a compound that, on administration, must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent; a precursor of a drug. (TAP) technology uses tumor-targeting antibodies to deliver a potent, cell-killing agent specifically to cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer . Four TAP compounds are in clinical testing - huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, and MLN MLN Million MLN Modern Language Notes (literary journal) MLN Management & Leadership Network (Northern Ireland) MLN Missouri League for Nursing MLN Main Listed Number 2704 and AVE9633, which are in development by ImmunoGen collaborators. Genentech, Centocor (a wholly-owned subsidiary of Johnson & Johnson), Biogen Idec, the sanofi-aventis Group, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim, and Abgenix have licensed the right to develop and/or test TAP compounds to specific targets; ImmunoGen also has a broader collaboration with the sanofi-aventis Group. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion